Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2004;6(2):74-77.
doi: 10.4088/pcc.v06n0205.

Prevalence of Metabolic Syndrome in Hispanic and Non-Hispanic Patients With Schizophrenia

Martha M. Kato  1 , M Beatriz Currier, Christina M. Gomez, Lacresha Hall, Mercedes Gonzalez-Blanco
Affiliations

Prevalence of Metabolic Syndrome in Hispanic and Non-Hispanic Patients With Schizophrenia

Martha M. Kato et al. Prim Care Companion J Clin Psychiatry. 2004.

Abstract

BACKGROUND: Metabolic syndrome, a constellation of truncal obesity, dyslipidemia, disturbed insulin and glucose metabolism, and hypertension, is associated with the development of diabetes mellitus and coronary heart disease. However, the prevalence of metabolic syndrome in Hispanic patients with schizophrenia and whether they differ from comparable non-Hispanic patients is uncertain. METHOD: This cross-sectional study, conducted from January 2002 to May 2002, included 48 patients with schizophrenia who were recruited from an outpatient psychiatric clinic. Metabolic syndrome was defined using the criteria of the Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. RESULTS: The prevalence of metabolic syndrome was 63% in all patients with schizophrenia. The metabolic syndrome was present in 41% of non-Hispanic patients and in 74% of Hispanic patients with schizophrenia. Metabolic syndrome was present in 70% of Cuban Americans and 88% of other Hispanic subgroups with schizophrenia. Metabolic syndrome was associated with waist circumference (p <.05) and high-density lipoprotein cholesterol (p <.05) in logistic regression analysis. CONCLUSIONS: These data suggest that schizophrenic patients have a 3-fold greater risk to develop metabolic syndrome than the general population. Hispanic schizophrenic patients have a significantly greater prevalence of metabolic syndrome than non-Hispanic schizophrenic patients (p <.05). An increased waist circumference is the strongest clinical correlate with metabolic syndrome in schizophrenic patients.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Prevalence of the Metabolic Syndrome by Ethnic Groups in Schizophrenic Patients
See this image and copyright information in PMC

References

    1. Henderson DC, Cagliero E, Gray C. Clozapine, diabetes mellitus, weight gain and lipid abnormalities: a five year naturalistic study. Am J Psychiatry. 2000;157:975–981. - PubMed
    1. Hagg S, Joelson L, and Mjörndal T. et al. Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications. J Clin Psychiatry. 1998 59:294–299. - PubMed
    1. Dixon L, Weiden P, and Delahanty J. et al. Prevalence and correlates of diabetes in national schizophrenia sample. Schizophr Bull. 2000 26:903–912. - PubMed
    1. Expert Panel on Detection and Treatment of High Blood Cholesterol in Adults. Executive summary of The Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol (Adult Treatment Panel III) JAMA. 2001;285:2486–2497. - PubMed
    1. Haffner SM, Valdez RA, and Hazuda HP. et al. Prospective analysis of the insulin-resistance syndrome (syndrome X). Diabetes. 1992 41:715–722. - PubMed